Invasive Breast Cancer and Risk of Recurrence Testing - MBPBCNRSK07Q.2020
Untitled Document


This activity is intended for pathologists participating in the multidisciplinary breast pathology (MBP) program or pathologists looking for more information on molecular analysis in breast pathology, specifically how genomic testing is currently being used to determine breast cancer recurrence risk.

Credit Type: CME, SAM, CPD
Duration: 1 hour 30 minutes
Launch Date: July 1, 2020
Expiration Date: June 30, 2023 12:00 AM (ET)
Pricing: Junior Member Fee: $10.00
MOC Category: Medical Knowledge, Patient Care

Description
Genomic testing for breast cancer recurrence risk has become an important part of clinical breast cancer care. This course provides an overview of risk of recurrence testing used in the diagnosis and treatment of invasive breast cancer. Statistics on cancer recurrence and clinical outcomes with chemotherapy, including data from the TAILORx trial, are reviewed. The course also provides the value and benefits of risk of recurrence testing, as well as how to determine which patients are good candidates for this testing. The different types of multigene assays and distinctions between them are reviewed, as well as an overview of IHC and protein profiling of cancer. The course includes ASCO and NCCN clinical practice guidelines for use of biomarkers to guide decisions on adjuvant systemic therapy for women with invasive breast cancer, and discusses the issues and concerns that continue to exist around risk of recurrence testing.

Objectives
After completing this SAM eligible activity and posttest, you should be able to:

  1. Define risk of recurrence testing.
  2. Describe the value and benefits of risk of recurrence testing.
  3. Identify several of the commercial multigene assays available and some distinctions between them.
  4. Explain which patients are good candidiates for risk of recurrence testing and how to make this determination.
  5. Explain when and how the application of selective antibody panels and routine IHC can be used to predict clinical behavior and outcomes in subsets of breast cancer patients.
  6. Identify the clinical practice guidelines for use of biomarkers to guide decisons on sdjuvant systemic therapy for women with invasive breast cancer.
  7. Explain some of the current issues and concerns surrounding risk of recurrence testing for breast cancer patients.

CME Information
Accreditation: The College of American Pathologists (CAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Category 1: The College of American Pathologists designates this internet enduring material educational activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the American Board of Pathology’s (ABPath) Maintenance of Certification (MOC) requirements for Self-Assessment Modules (SAMs).

Continuing Professional Development (CPD), Section 3 Credit
Accreditation in Canada: This event is an Accredited Self Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, approved by the Canadian Association of Pathologists - Association Canadienne des Pathologistes. You may claim a maximum of 1.5 hour(s) equivalent to 4.5 credit(s).

Passing Requirements
You have a total of three opportunities to take and pass the posttest. If you correctly answer 70% or more of the posttest items, you may claim credit. CME/SAM credit can be applied to the American Board of Pathology (ABPath) Self-Assessment Module (SAM) requirements.You must pass the posttest to claim credit; therefore, if you do not pass, you cannot claim any credit.

Attention Canadian Participants: You have three opportunities to take and pass the posttest. If you do not pass the posttest after three attempts, you may still claim CPD credit (self-assessment program credits) for this activity. Please contact a representative of the CAP Learning Division at 800-323-4040 option 1 or education@cap.org with the name of this activity and the date completed to request a letter of participation.

Payment Information
To pay with a check, print a copy of this page and send it with your check to the address below. You will be notified when your payment has been processed and you have been registered into the activity.

College of American Pathologists
Education Division
325 Waukegan Road
Northfield, IL 60093-2750

Refund Policy
Refunds will be handled on an exception basis. Please submit your request to the CAP in writing via email at education@cap.org or fax at 847-832-8006.

Technical Requirements
Pop-up blockers must be turned off.

CAP Learning has recognized that some Veteran’s Administration, US Government, and military participants may have difficulty accessing the online assessment portion of this activity. If you experience difficulty or have any questions, please contact a representative of the CAP Learning Division at 800-323-4040 option 1 or education@cap.org.

Availability
This activity and evaluation are available July 1, 2020, and expire June 30, 2023, at 12:00 AM (ET). You MUST claim credit by this date and time.

CC: MBPBCNRSK07Q.2020






Non-Member Price:   $65.00  
 
Member Price:  $50.00   


Invasive Breast Cancer and Risk of Recurrence Testing